Immunitrack proudly announces collaboration with AdaptVac Aps and the University of Copenhagen in a new article ‘First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2’.
Summary of the article
The SARS-CoV-2 virus has caused deaths worldwide. Various vaccines against the virus have been developed and implemented to protect the population globally. Most vaccines target the whole spike protein to induce an antibody response. Capsid virus-like particles (cVLP) have in previous studies shown to be safe and immunogenic and could possibly counter pandemics. The aim of this article was to clinically test a novel cVLP COVID-19 vaccine expressing the RBD (receptor binding domain) from Spike protein in humans.
In this first-in-human clinical trial with the SARS-CoV-2 vaccine ABNCoV2, on 45 recruited participants, it was found that the vaccine was well-tolerated and had the ability to induce a high IgG antibody response against the SARS-CoV-2 RBD. Serum samples revealed functional activity against various of the SARS-CoV-2 variants, and the antibody concentrations stayed high for several months. Virus neutralization activity appeared after the second vaccination and with a vaccine dose that was comparable to the WHO standard 20/136. In addition, there was an induction of T cell response with a T-helper-1 pattern.
These new findings indicate that ABNCoV2 has promising effects and could possibly in the future be a novel cVLP-based COVID-19 vaccine on the market.
In this study, Immunitrack analyzed the T cell response against the receptor binding domain (RBD) of the SARS-CoV2 Spike glycoprotein as described in this study https://www.immunitrack.com/vaccines/spike . NeoScreen was performed on the RBD proteins, to select peptides to test for T-cell reactivity via intracellular cytokine staining (ICS) as shown in figure 1.